Background: CC49 is a monoclonal antibody directed against a pancarcinoma antigen (TAG-72) expressed by colorectal cancers. The use of murine CC49 in radioimmunoguided surgery (RIGS) was problematic because of the human anti-mouse antibodies (HAMA) generated. This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49ΔCH2). Methods: After thyroid blockade, 1 mg of HuCC49ΔCH2 radiolabeled with 2 mCi of iodine-125 was administered. All patients subsequently underwent traditional exploration followed by a survey with the gamma-detecting probe. In five patients, exploration was performed 10 to 24 days after injection, when precordial counts were sufficiently low (<30 counts per 2 seconds [cp2s]). Traditionally suggestive and probe-positive tissue was biopsied or excised and examined for the presence of carcinoma, when considered appropriate by the operating surgeon. Serum was assessed for HAMA. Results: Seventeen sites were identified as suggestive of carcinoma on traditional exploration and 21 by RIGS. Of these, pathologic correlation was obtained in 15. The sensitivity of RIGS was 92%, and the positive predictive value was 100%. None of the patients expressed significant HAMA. Conclusions: This initial study indicates that the HuCC49ΔCH2 monoclonal antibody, when used with RIGS, is safe and sensitive in detecting recurrent intra-abdominal colon cancer.
- Colorectal carcinoma
- Monoclonal antibody
ASJC Scopus subject areas
Pilot study using a humanized CC49 monoclonal antibody (HuCC49ΔC H2) to localize recurrent colorectal carcinoma. / Agnese, Doreen M.; Abdessalam, Shahab F.; Burak, William E.; Arnold, Mark W.; Soble, Denise; Hinkle, George H.; Young, Donn; Khazaeli, M. B.; Martin, Edward W.In: Annals of Surgical Oncology, Vol. 11, No. 2, 01.12.2004, p. 197-202.
Research output: Contribution to journal › Article